Guangdong Biolight Meditech's low P/S ratio may be due to expected revenue decline. The company's shrinking revenue and the industry's projected growth are key factors. Shareholders accept the low P/S, conceding future revenue may not surprise. If revenue trends continue, share price may not move strongly in either direction soon.